Gemcitabine's Effect on Tumor Cells and Radiation Sensitivity
Author Information
Author(s): Pauwels Bea, Korst Annelies EC, Pattyn Greet GO, Lambrechts Hilde AJ, Kamphuis Juliette AE, De Pooter Christel MJ, Peters Godefridus J, Lardon Filip, Vermorken Jan B
Primary Institution: University of Antwerp (UA/UZA)
Hypothesis
The study investigates the relationship between deoxycytidine kinase (dCK) activity and the radiosensitising effect of gemcitabine in various human tumor cell lines.
Conclusion
Gemcitabine enhances radiosensitivity in tumor cells, but dCK activity is not the most critical factor in this process.
Supporting Evidence
- Gemcitabine shows a clear concentration-dependent radiosensitising effect in various tumor cell lines.
- The degree of radiosensitisation varies by cell line and correlates with the sensitivity to gemcitabine's cytotoxic effects.
- dCK activity varied significantly among the cell lines tested.
Takeaway
Gemcitabine helps make cancer cells more sensitive to radiation, but how much dCK enzyme is present in the cells isn't the most important part of that process.
Methodology
Tumor cells were treated with gemcitabine and then exposed to radiation, with cell survival measured using the sulforhodamine B test.
Limitations
The range of dCK activity in the cell lines may not have been large enough to establish a strong correlation with radiosensitisation.
Participant Demographics
Human tumor cell lines from various tissues including bladder, lung, breast, and pancreas.
Statistical Information
P-Value
0.11
Statistical Significance
p = 0.11
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website